Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | POLB | P06746 | 4/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 5/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102261 | 0.77 | MAPT (0.71) | MAPTPOLBMEN1KMT2APKM | |
| SCHEMBL16084848 | 0.74 | MAPT (0.83) | MAPTPOLBMEN1KMT2APKM | |
| SCHEMBL17712411 | 0.73 | MAPT (0.85) | MAPTPOLBMEN1KMT2APKM | |
| SCHEMBL16187793 | 0.71 | RXFP1 (0.72) | MAPTPOLBMEN1KMT2APKM | |
| SCHEMBL1102053 | 0.67 | MAPT (0.69) | MAPTPOLBMEN1KMT2ARXFP1 | |
| SCHEMBL14119627 | 0.66 | POLB (0.66) | MAPTPOLBMEN1KMT2APKM | |
| SCHEMBL3456739 | 0.66 | PKM (0.74) | MAPTPOLBMEN1KMT2APKM | |
| SCHEMBL1102056 | 0.65 | POLB (0.60) | MAPTPOLBMEN1KMT2APKM | |
| SCHEMBL24272422 | 0.64 | MAPT (0.58) | MAPTPOLBMEN1KMT2APKM | |
| SCHEMBL11887781 | 0.64 | POLB (0.66) | MAPTPOLBMEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | MAPT 2982/4885POLB 2362/4885MEN1 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.